New drug aimed at lung cancer shows promise in early trial

NCT ID NCT05577715

Terminated Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested an experimental drug called MORAb-202 in 31 people with a type of advanced lung cancer (non-small cell lung cancer adenocarcinoma) that had gotten worse after other treatments. The drug is designed to target and kill cancer cells while sparing healthy ones. The trial was stopped early, but researchers were looking at how safe the drug is and whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MORAb-202 (Farletuzumab ecteribulin)
What this could lead to: If it works, this could point toward a new treatment option for people with a certain type of advanced lung cancer that has stopped responding to other therapies.
What could go wrong: This was a small, early-phase trial that was terminated early, so results are limited. The drug may cause side effects and may not shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Henry Ford Hospital

Detroit, Michigan, 48202-2608, United States
Local Institution - 0001

Marietta, Georgia, 30060, United States
Local Institution - 0002

Kansas City, Missouri, 64132, United States
Local Institution - 0005

Louisville, Kentucky, 40241-2832, United States
Local Institution - 0007

Orange, California, 92868-3201, United States
Local Institution - 0010

Orange City, Florida, 32763-8316, United States
Local Institution - 0011

Charlotte, North Carolina, 28207, United States
Local Institution - 0012

Ballarat Central, Victoria, 3350, Australia
Local Institution - 0014

Toulon, 83056, France
Local Institution - 0015

Suresnes, 92151, France
Local Institution - 0017

Rouen, 76000, France
Local Institution - 0018

Madrid, 28041, Spain
Local Institution - 0019

Majadahonda (Madrid), M, 28222, Spain
Local Institution - 0020

Málaga, MA, 29010, Spain
Local Institution - 0021

Barcelona, 08036, Spain
Local Institution - 0022

Murdoch, Western Australia, 6150, Australia
Local Institution - 0023

Santiago, 7500921, Chile
Local Institution - 0025

Barcelona, 08035, Spain
Local Institution - 0026

Santiago de Compostela, 15706, Spain
Local Institution - 0027

Recoleta, 8420383, Chile
Local Institution - 0028

Providencia, SA, 7500653, Chile
Local Institution - 0030

Independencia, 8380456, Chile
Local Institution - 0031

Seville, 41013, Spain
Local Institution - 0033

Fairfax, Virginia, 22031-4629, United States
Local Institution - 0034

Arlington, Texas, 76012-2510, United States
Local Institution - 0035

Lone Tree, Colorado, 80124, United States
Local Institution - 0036

Roeselare, 8800, Belgium
Local Institution - 0038

Villejuif, 94805, France
Local Institution - 0039

Mons, WHT, 7000, Belgium
Local Institution - 0040

Wollongong, NS, 2500, Australia
Local Institution - 0043

Clermont, Florida, 34711-6699, United States
Local Institution - 0044

Silver Spring, Maryland, 20904-7917, United States
Local Institution - 0045

Flower Mound, Texas, 75028-1713, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.